May 6, 2008

Huge Upside for Acadia Pharmaceuticals

Zacks has a feature on Acadia Pharmaceuticals, a small company that has five drug programs in clinical and preclinical development directed at large unmet medical needs and major commercial markets.

They give the stock a fair value of $20 a share, but admit that this may be a high estimate.

No comments: